The Asia Pacific Infectious Respiratory Disease Diagnostics Market would witness market growth of -4.9% CAGR during the forecast period (2022-2028).
Respiratory infections are frequently spread via saliva and mucus, which are typically discharged when someone coughs, sneezes, or laughs. A few of the pathogens that cause respiratory infections can also spread through airborne droplets and through travel. Additionally, some persons can contract an infection by touching contaminated hands or any lingering germs on the surface. Coronavirus diseases (COVID-19), Middle East Respiratory Syndrome (MERS), severe acute respiratory syndrome (SARS), pneumonia, influenza diseases, tuberculosis, whooping cough (Pertussis), enterobius, and chronic obstructive pulmonary disease are just a few examples of the infectious respiratory diseases.
The prevalence of respiratory infectious illnesses such as influenza, TB, pertussis, chronic obstructive pulmonary disease, and MERS is becoming a major concern across the globe. The occurrence of lung diseases including tuberculosis and pneumonia as well as other chronic obstructive pulmonary disorders like chronic bronchitis, emphysema, and asthma is expected to climb quickly.
Virologic laboratory techniques that either isolate and identify the pathogens or track the levels of antibodies in body fluids are the foundation of the current protocols used to validate the diagnosis of viral infection. These procedures entail laboratory procedures that call for specialized tools and technological know-how. Additionally, the preanalytical steps add to the lengthy turnaround time, delaying the results and the associated diagnostic and therapeutic choices.
India has made important improvements in how healthcare is provided there. It has been one of the largest industries in terms of employment as well as revenue and is expanding quickly. With the primary goal of reducing mortality and morbidity from various communicable & non-communicable diseases, the public healthcare system primarily focuses on providing primary healthcare through community-level health programs.
The China market dominated the Asia Pacific Infectious Respiratory Disease Diagnostics Market by Country in 2021; thereby, achieving a market value of $3.6 billion by 2028. The Japan market is estimated to grow at a CAGR of -5.5% during (2022 - 2028). Additionally, The India market would exhibit a CAGR of -4.3% during (2022 - 2028).
Based on Product Type, the market is segmented into Consumables, Instruments (Imaging Tests, Respiratory Measurement Devices, and Others), Services. Based on Application, the market is segmented into SARS/COVID 19, Influenza, RSV (Respiratory Syncytial Virus), Tuberculosis, Streptococcus Testing, and Others. Based on Sample Type, the market is segmented into Saliva, Anterior Nasal Region, Blood, Nasopharyngeal Swabs (NPS), and Others. Based on Technology, the market is segmented into Molecular Diagnostics, Microbiology, Immunoassay, and Others. Based on End-use, the market is segmented into Diagnostic Laboratories, Hospitals, and Physician Offices & Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Infectious Respiratory Disease Diagnostics Market is Projected to reach USD 37.2 Billion by 2028, at a CAGR of -5.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, Siemens Healthineers AG (Siemens AG), Thermo Fisher Scientific, Inc., Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Qiagen N.V., Bio-Rad Laboratories, Inc., Danaher Corporation, Quidel Corporation
By Product Type
By Application
By Sample Type
By Technology
By End Use
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 